• Seminars in oncology · Feb 1999

    Review

    The current role and future prospects of paclitaxel in the treatment of small cell lung cancer.

    • J D Hainsworth and F A Greco.
    • Sarah Cannon-Minnie Pearl Cancer Center, Nashville, TN 37203, USA.
    • Semin. Oncol. 1999 Feb 1; 26 (1 Suppl 2): 60-6.

    AbstractWhen combination regimens containing a platinum compound and etoposide are used, median survivals in patients with extensive- and limited-stage small cell lung cancer are 7 to 10 months and 15 to 20 months, respectively. A recent randomized trial demonstrated equivalent efficacy and decreased toxicity with carboplatin/etoposide compared with cisplatin/etoposide. Because of excellent single-agent activity, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been recently added to various platinum/etoposide combinations. Phase I/II studies with paclitaxel/cisplatin/etoposide and paclitaxel/carboplatin/etoposide have demonstrated excellent activity with acceptable toxicity. Ongoing phase III trials will better define the contribution of paclitaxel to standard platinum/etoposide regimens. In addition, phase II trials of novel paclitaxel combinations (e.g., paclitaxel/topotecan, paclitaxel/carboplatin/topotecan) are ongoing.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…